Identifying Changes in Regulation of Disease-Related Genes
News Nov 11, 2005
The Gene Expression Center Martinsried (GECM) at IMGM Laboratories has announced that it is using the Applied Biosystems 1700 Chemiluminescent Microarray Analyzer with the PANTHER™ Protein Classification System to analyse disease-related genes.
The GECM offers contract research that typically involves elucidating the changes in gene expression between different cellular states, and uses the Applied Biosystems 7900HT Fast Real-Time PCR System with Micro Fluidic cards for validation of the results.
“There are several features of the 1700 Microarray Analyzer that I particularly like,” said Dr Mirko Vanetti, CEO of IMGM.
“Firstly, the platform's sensitivity is much higher because it works with chemiluminescence instead of fluorescence, improving the detection of genes that are expressed in low amounts, notably regulatory proteins.”
“Secondly, it offers an additional 8,000 genes that we can screen, which are not present on any other commercial microarray.”
“The analyser also has a fluorescence mechanism that accurately detects and compensates for morphological spot irregularities and, as a result, our data are much more reliable.”
“Our raw data are imported into the PANTHER database so we can quickly and easily identify which specific cellular pathways are over or under-represented in one cellular state compared with another.”
“Using the system's annotation with the database makes it much easier not only to extract results, but also to understand their meaning.”
“People do not want to see long lists of genes whose expression levels alter, they want to receive results in a readable format.”
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.